Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 65487

Next Previous
Drug Profile

S 65487

Alternative Names: S 65487/VOB 560; S-65487; VOB-560

Latest Information Update: 10 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier; Vernalis
  • Developer ADIR; Institut de Recherches Internationales Serviers; Novartis; Servier
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Jul 2024 Novartis terminates a phase-Ib trial in Acute myeloid leukaemia, Multiple myeloma and Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Belgium, Spain, South Korea, Japan, Italy, Israel, Hong Kong, Finland and USA due to business reason (IV), (NCT04702425)
  • 13 Jun 2024 Interim efficacy and adverse events data from a phase I/II trial in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 11 Apr 2024 53466 S 65487 is still in I/II trials for Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Multiple Myeloma in France, United Kingdom, Spain, Australia (NCT03755154)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top